CAS No. |
376653-43-9 |
中文名称 |
(6R,7R)-7-[(Z)-2-(5-氨基-1,2,4-噻二唑-3-基)-2-(羟亚氨基)乙酰氨基]-3-[(E)-((R)-1'-(((5-甲基-2-氧代-1,3-二氧戊环-4-基)甲氧基)羰基)-2-氧代-[1,3'-联吡咯烷]-3-亚基)甲基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸 |
英文名称 |
(6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetamido)-3-((E)-((R)-1'-(((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)-2-oxo-[1,3'-bipyrrolidin]-3-ylidene)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
别名 |
Ceftobiprole medocaril;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-aMino-1,2,4-thiadiazol-3-yl)-2-(hydroxyiMino)acetyl]aMino]-3-[[(E,3'R)-1'-[[(5-Methyl-2-oxo-1,3-dioxol-4-yl)Methoxy]carbonyl]-2-oxo[1,3'-bipyrrolidin]-3-ylidene]Methyl]-8-oxo-,(6R,7R)-;BAL5788;Ceftobiprole medocaril USP/EP/BP;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino]-3-[[(E,3'R)-1'-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1;BAL-5788,Inhibitor,penicillin,cephalosporin,inhibit,gram-positive,pyrrolidinone,BAL 5788,MRSA,Ceftobiprole medocaril,Bacterial,vancomycin,pathogens,staphylococci,gram-negative,VRSA,methicillin,Prodrug;Valine Impurity 146 |
标准英文名 |
(6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetamido)-3-((E)-((R)-1'-(((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)-2-oxo-[1,3'-bipyrrolidin]-3-ylidene)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
MDL No. |
MFCD16621102 |
分子式 |
C26H26N8O11S2 |
分子量 |
690.67
|
精确分子量 |
690.12
|
SMILES |
CC1=C(COC(=O)N2CC[C@@H](N3CC/C(=C\C4=C(C(=O)O)N5C(=O)[C@@H](NC(=O)/C(=N\O)C6=NSC(N)=N6)[C@H]5SC4)C3=O)C2)OC(=O)O1 |
标准SMILES |
CC1OC(=O)OC=1COC(=O)N1C[C@@H](CC1)N1CC/C(=C\C2CS[C@@H]3[C@H](NC(=O)/C(=N\O)/C4N=C(N)SN=4)C(=O)N3C=2C(O)=O)/C1=O |
用途 |
Ceftobiprole medocaril is a prodrug of ceftobiprole, a broad-spectrum cephalosporin antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA). It is indicated for the treatment of complicated skin and skin structure infections and has been approved for this use in Canada and Switzerland. Additionally, a marketing authorization application for the treatment of pneumonia was submitted to the European Medicines Agency (EMA). |
InChIKey |
HFTSMHTWUFCYMJ-YIOMYIDASA-N |